Methods of treating lennox-gastaut syndrome using fenfluramine

Abstract

A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Lennox Syndrome patients are treated at a preferred dose of less than about 2.0 to about 0.01 mg/kg/day.

That which is claimed is: 
     
         1 . A method of treating, and/or preventing symptoms of Lennox-Gastaut syndrome (Lennox Syndrome) in a patient diagnosed with Lennox-Gastaut syndrome, comprising:
 administering a pharmacologically effective dose of fenfluramine or a pharmaceutically acceptable salt thereof to the patient.   
     
     
         2 . The method of  claim 1 , wherein the dose is in a range of from 10.0 mg/kg/day to 0.01 mg/kg/day. 
     
     
         3 . The method of  claim 2 , wherein the dose is administered in a dosage form selected from the group consisting of oral, injectable, transdermal, inhaled, nasal, rectal, vaginal and parenteral delivery. 
     
     
         4 . The method of  claim 3 , wherein the dosage form is an oral solution in an amount selected from the group consisting of 120 mg or less, 60 mg or less, and 30 mg or less. 
     
     
         5 . The method as claimed in  claim 4  wherein the dosage form consists essentially only of fenfluramine as the active ingredient. 
     
     
         6 . The method as claimed in  claim 1 , further comprising:
 administering a co-therapeutic agent selected from the group consisting of carbamazepine, ethosuximide, fosphenytoin, lamotrigine, levetiracetam, phenobarbital, progabide, topiramate, stiripentol, valproic acid, valproate, verapamil, and benzodiazepines such as clobazam, clonazepam, diazepam, ethyl loflazepate, lorazepam, midazolam and a pharmaceutically acceptable salt or base thereof.   
     
     
         7 . The method of  claim 1 , wherein the symptom is preventing and/or ameliorating seizures in a patient diagnosed with Lennox-Gastaut syndrome, and wherein the fenfluramine is formulated with a pharmaceutically acceptable carrier and an effective dose is less than 10.0 mg/kg/day to 0.01 mg/kg/day. 
     
     
         8 . The method of  claim 1  wherein the dose is selected from the group consisting of 120 mg or less, 60 mg or less, and 30 mg or less, and wherein the dose is administered in a dosage form selected from the group consisting of forms for oral, injectable, transdermal, inhaled, nasal, rectal, vaginal and parenteral delivery. 
     
     
         9 . The method as claimed in  claim 2 , wherein the fenfluramine is the only active ingredient administered to the patient. 
     
     
         10 . The method of  claim 9 , further comprising:
 administering a co-therapeutic agent selected from the group consisting of carbamazepine, ethosuximide, fosphenytoin, lamotrigine, levetiracetam, phenobarbital, topiramate, stiripentol, valproic acid, valproate, verapamil, and benzodiazepines such as clobazam, clonazepam, diazepam, lorazepam, and midazolam and a pharmaceutically acceptable salt or base thereof.   
     
     
         11 . The method of  claim 10  wherein the co-therapeutic agent is a combination of stiripentol, clobazam, and valproate. 
     
     
         12 . The method of  claim 11 , wherein the co-administration of the stiripentol, clobazam and valproate increases fenfluramine blood levels by 100% or more relative to fenfluramine blood levels obtained in the absence of the co-administration of stiripentol, clobazam and valproate, and further wherein blood levels of a metabolized of fenfluramine are decreased relative to levels of a flenfluramine metabolite obtained in the absence of the co-administration of stiripentol, clobazam and valproate. 
     
     
         13 . The method of  claim 10 , wherein the co-therapeutic agent is stiripentol. 
     
     
         14 . A kit, comprising:
 a container comprising a plurality of doses of a formulation comprising a pharmaceutically acceptable carrier and an active ingredient comprising fenfluramine;   instructions for treating the patient diagnosed with LGS by withdrawing the formulation from the container, and administering the formulation to the patient.   
     
     
         15 . The kit as claimed in  claim 14 , wherein:
 the formulation is an oral solution comprising 2.5 milligram of fenfluramine in each milliliter of liquid solution; and   the instructions indicate dosing the patient based on patient weight and volume of oral solution administered.   
     
     
         16 . The kit as claimed in  claim 14 , wherein the formulation is a solid oral formulation selected from the group consisting of: a tablet, a disintegrating table, a capsule, a lozenge, and a sachet. 
     
     
         17 . The kit as claimed in  claim 14 , wherein said formulation is provided in a transdermal patch. 
     
     
         18 . A kit, comprising:
 a container comprising a plurality of doses of a formulation comprising a pharmaceutically acceptable carrier and an active ingredient comprising fenfluramine;   a container comprising a plurality of doses of a formulation comprising a pharmaceutically acceptable carrier and an active ingredient comprising stiripentol;   instructions for treating a patient.